Company: PRTA
Filing Date: 2025-08-04
Form Type: 10-Q
Source: 0001559053-25-000031
Chunk: 9

Company: PROTHENA CORP PUBLIC LTD CO
Filing Date: 2025-08-04
Form: 10-Q
Item: Part I, Item 1
Chunk 9
---
 $           3,339      $          3,216         $      $         $     
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
                                                        Total                  2025                  2026      2027      2028  
  Contractual obligations under license agreements      309                    59                      70      70        55    
  Obligations under restructuring plan                             30,330                30,039       291      —         —     
  Total                                                 $          33,978      $         33,314         $      $         $     

________________

(1)Purchase obligations consist of non-cancelable purchase commitments to suppliers and contract research organizations.

(2) Includes cash obligations under our restructuring plan. For additional information, see Note 11, “ Restructuring” to the Condensed Consolidated Financial Statements.

7. Significant Agreements

Roche License Agreement

In December 2013, the Company through its wholly owned subsidiary Prothena Biosciences Limited and Prothena Biosciences Inc entered into a License, Development, and Commercialization Agreement (the “ License Agreement”) with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. (together, “ Roche”) to develop and commercialize certain antibodies that target α- synuclein, including prasinezumab, which are referred to collectively as “ Licensed Products.” Upon the effectiveness of the License Agreement in January 2014, the Company granted to Roche an exclusive, worldwide license to develop, make, have made, use, sell, offer to sell, import and export the Licensed Products. The Company retained certain rights to conduct development of the Licensed Products and a n option to co-promote prasinezumab in the U. S. During the term of the License Agreement, the Company and Roche will work exclusively with each other to research and develop antibody products targeting alpha-synuclein (or α- synuclein) potentially including incorporation of Roche’s proprietary Brain Shuttle™ technology to potentially increase delivery of therapeutic antibodies to the brain. The License Agreement provided for Roche making an upfront payment to the Company of $ 30.0 15.0 30.0 60.0

For prasinezumab, Roche is obligated to pay:

• up to $ 290.0

• up to $ 155.0

• up to $ 175.0